Alansari Khalid, Davidson Bruce L, Holick Michael F
Department of Emergency Medicine, Sidra Medicine, Doha, Qatar.
Department of Emergency Medicine, Weill Cornell Medicine-Qatar, Doha, Qatar.
J Allergy Clin Immunol Glob. 2025 May 21;4(3):100497. doi: 10.1016/j.jacig.2025.100497. eCollection 2025 Aug.
A role for vitamin D supplementation in deficient/insufficient asthmatic children is controversial.
We sought to compare high-dose intramuscular (IM) + daily oral maintenance vitamin D dose versus daily oral maintenance vitamin D dose for preventing asthma exacerbations in prospectively randomized vitamin D-deficient/insufficient children aged 5 to 14 years with moderate to severe asthma.
This is an accessory analysis from a larger vitamin D supplementation trial, analyzing results of the randomized stratum of older children receiving the high dose presenting with emergency department (ED) visits for asthma and baseline blood 25-hydroxyvitamin D concentration less than or equal to 25 ng/mL. Blinded randomization to clinic-administered IM 600,000 IU every 3 months + 400 IU orally daily at home or 400 IU orally daily at home (control group) was performed. The primary outcome was need for unplanned ED asthma exacerbation visit over 0 to 12 months for moderate to severe asthma.
A total of 122 children aged 5 to 14 years (61 high-dose IM 600,000 IU + Oral and 61 Oral-Only) completed a 12-month treatment. Baseline 25-hydroxyvitamin D level was less than 20 ng/mL in 84% of them. Over months 0 to 12, as the Oral-Only group was slowly repleted, the IM + Oral group remained superior to the Oral-Only group (40 [66%] with unplanned ED visits vs 50 [82%]; relative risk, 0.80 [95% CI, 0.65-1.0]; absolute risk reduction, 16% [95% CI, 1%-31%]; number needed to treat, 6.3). Over months 0 to 3, a secondary outcome, the IM 600,000 IU + Oral supplementation group had a reduction in ED visits compared with the Oral-Only group (21 [34%] vs 38 [58%]; relative risk, 0.55 [95% CI, 0.36-0.84]; absolute risk reduction, 28% [95% CI, 9%-45%]; number needed to treat, 3.4).
A dose of IM 600,000 IU vitamin D every 3 months significantly reduced unplanned ED visits for asthma for vitamin D-deficient/insufficient asthmatic children aged 5 to 14 years over months 0 to 12 and months 0 to 3.
补充维生素D在维生素D缺乏/不足的哮喘儿童中所起的作用存在争议。
我们旨在比较高剂量肌肉注射(IM)+每日口服维持剂量维生素D与每日口服维持剂量维生素D,对前瞻性随机分组的5至14岁维生素D缺乏/不足且患有中度至重度哮喘的儿童预防哮喘发作的效果。
这是一项来自一项更大规模维生素D补充试验的辅助分析,分析的是年龄较大儿童随机分组层的结果,这些儿童接受高剂量维生素D治疗,因哮喘到急诊科就诊,且基线血25-羟维生素D浓度小于或等于25 ng/mL。进行了盲法随机分组,一组为每3个月门诊肌肉注射600,000 IU维生素D+在家每日口服400 IU(对照组),另一组为在家每日口服400 IU。主要结局是0至12个月内中度至重度哮喘患儿计划外到急诊科就诊的哮喘发作次数。
共有122名5至14岁儿童(61名接受高剂量肌肉注射600,000 IU+口服组和61名仅口服组)完成了12个月的治疗。其中84%的儿童基线25-羟维生素D水平低于20 ng/mL。在0至12个月期间,随着仅口服组维生素D水平缓慢回升,肌肉注射+口服组仍优于仅口服组(40例[66%]有计划外急诊科就诊,而仅口服组为50例[82%];相对危险度,0.80[95%CI,0.65 - 1.0];绝对危险度降低,16%[95%CI,1% - 31%];需治疗人数,6.3)。在0至3个月期间,作为次要结局,肌肉注射600,000 IU+口服补充剂组与仅口服组相比,急诊科就诊次数减少(21例[34%]对38例[58%];相对危险度,0.55[95%CI,0.36 - 0.84];绝对危险度降低,28%[95%CI,9% - 45%];需治疗人数,3.4)。
每3个月肌肉注射600,000 IU维生素D可显著减少5至14岁维生素D缺乏/不足的哮喘儿童在0至12个月以及0至3个月期间计划外的哮喘急诊科就诊次数。